Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dyrk1a inhibition with the Novel Compound DYR533: A Cross-Disease Therapeutic Strategy Targeting Amyloidosis, Tau Pathogenesis, and Neuroinflammation.

bioRxiv : the preprint server for biology·2026
Same author

Idiopathic isolated adrenocorticotropic hormone deficiency: a systematic review of a heterogeneous and underreported disease.

Pituitary·2023
Same author

Synthesis and evaluation of druglike parameters via in silico techniques for a series of heterocyclic monosquarate-amide derivatives as potential carboxylic acid bioisosteres.

Bioorganic & medicinal chemistry·2023
Same author

Patient empowerment improves follow-up data collection after fetal surgery for spina bifida: institutional audit.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2023
Same author

Conservative management of complicated Rathke's cleft cyst mimicking pituitary apoplexy.

Endocrinology, diabetes & metabolism case reports·2022
Same author

Neuroprotection is improved by watertightness of fetal spina bifida repair in the sheep model.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2022

Related Experiment Video

Updated: May 11, 2026

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

Defining pseudoprogression in glioblastoma multiforme.

E Van Mieghem1, A Wozniak, Y Geussens

  • 1Leuven Cancer Institute, KU Leuven and University Hospitals Leuven, Leuven, Belgium.

European Journal of Neurology
|May 18, 2013
PubMed
Summary

Pseudoprogression in glioblastoma multiforme (GBM) is common after radiotherapy and temozolomide (RT/TMZ) treatment. Its incidence varies by criteria, but pseudoprogression does not impact patient survival outcomes.

Keywords:
chemotherapyglioblastomapseudoprogressionradiotherapytemozolomide

More Related Videos

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Related Experiment Videos

Last Updated: May 11, 2026

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Area of Science:

  • Neuro-oncology
  • Radiation Oncology
  • Clinical Neurology

Background:

  • Pseudoprogression is frequently observed in glioblastoma multiforme (GBM) patients undergoing postoperative radiotherapy and temozolomide (RT/TMZ).
  • The precise definition, incidence, timing, and impact of pseudoprogression on treatment and outcomes require further clarification.

Purpose of the Study:

  • To compare the incidence of pseudoprogression using liberal versus stringent criteria.
  • To evaluate pseudoprogression in GBM patients treated before and after the introduction of RT/TMZ therapy.

Main Methods:

  • Retrospective review of 136 unselected GBM patients.
  • Comparison of pseudoprogression rates based on two distinct sets of diagnostic criteria.
  • Analysis of patient cohorts treated with RT/TMZ versus RT alone.

Main Results:

  • Pseudoprogression incidence was 12% (stringent criteria) and 23% (liberal criteria) in the RT/TMZ cohort.
  • Only one case of pseudoprogression occurred in the RT-alone group.
  • Median survival was 28 months for patients with pseudoprogression versus 12 months for those without.

Conclusions:

  • The reported incidence of pseudoprogression in GBM patients treated with RT/TMZ is highly dependent on the diagnostic criteria employed.
  • Regardless of the criteria used, pseudoprogression did not significantly alter overall patient survival.